Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | DPYD | Q12882 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymine SCHEMBL2476233 | 1.00 | ATAD2 (0.58) | ATAD2DYRK1AADORA2AADORA1NOS3 | |
| Thymine SCHEMBL3657360 | 0.93 | ATAD2 (0.50) | ATAD2DYRK1AADORA2AADORA1NOS3 | |
| Thymine SCHEMBL5588329 | 0.91 | ATAD2 (0.47) | ATAD2DYRK1AADORA2AADORA1DPYD | |
| Thymine SCHEMBL13280351 | 0.89 | ATAD2 (0.45) | ATAD2DYRK1ALMNAHTTALDH1A1 | |
| Guanine SCHEMBL4007020 | 0.85 | ATAD2 (0.41) | ATAD2DYRK1ALMNAALDH1A1MAPT | |
| Adenine SCHEMBL4579096 | 0.85 | ATAD2 (0.41) | ATAD2 | |
| Guanine SCHEMBL23880590 | 0.84 | PNP (0.55) | ATAD2ALDH1A1MAPTMEN1KMT2A | |
| Guanine SCHEMBL2526275 | 0.84 | PNP (0.55) | ATAD2ALDH1A1MAPTMEN1KMT2A | |
| Guanine SCHEMBL20518478 | 0.84 | PNP (0.55) | ATAD2ALDH1A1MAPTMEN1KMT2A | |
| Guanine SCHEMBL17597606 | 0.84 | PNP (0.55) | ATAD2ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523742-A1 | A RISK STRATIFICATION METHOD FOR A PATIENT HAVING A POLYMORPHISM | Helicalhelp LLC (US) | 2019-08-14 | — | — | EP | claimed |
| WO-2018067897-A1 | A RISK STRATIFICATION METHOD FOR A PATIENT HAVING A POLYMORPHISM | HelicalHelp LLC (US) | 2018-04-12 | — | — | WO | claimed |
| WO-2006102970-A9 | MODIFIED SHORT INTERFERING RNA | QIAGEN GMBH (DE) | 2016-05-26 | — | — | WO | claimed |
| EP-2121717-A2 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON CENTERS AND METHODS OF USE | Institut De Recherches Cliniques De Montreal (CA) | 2009-11-25 | — | — | EP | claimed |
| US-20090197332-A1 | Modified Short Interfering RNA | QIAGEN GMBH (DE) | 2009-08-06 | — | — | US | claimed |
| WO-2008087558-A2 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON CENTERS AND METHODS OF USE | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2008-07-24 | — | — | WO | claimed |
| EP-1863912-A2 | MODIFIED SHORT INTERFERING RNA | Qiagen GmbH (DE) | 2007-12-12 | — | — | EP | claimed |
| WO-2006102970-A2 | MODIFIED SHORT INTERFERING RNA | QIAGEN GMBH (DE) | 2006-10-05 | — | — | WO | claimed |
| EP-1652528-A1 | ACTIVATED CARBON INFUSION SOLUTION, PREPARATION METHOD THEREFOR AND USE THEREOF FOR THE MANUFACTURE OF DRUG FOR TREATING CANCER | Chen, Xiaochuan (CN) | 2006-05-03 | — | — | EP | claimed |
| US-20050123613-A1 | Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer | CHEN XIAOCHUAN (CN) | 2005-06-09 | — | — | US | claimed |
| EP-0850949-A2 | Novel derivatives for use in nucleic acid sequencing | INSTITUT PASTEUR (FR) | 1998-07-01 | — | — | EP | claimed |
| US-5591733-A | TREATMENT OF ANXIETY, STRESS, INSOMNIA, SEIZURES, STEROIDS, ACTIVE AT GAMMA-AMINOBUTYRIC ACID RECEPTORS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1997-01-07 | — | — | US | claimed |
| EP-0554436-A4 | — | — | 1994-01-12 | — | — | EP | claimed |
| EP-0554436-A1 | GABA RECEPTOR MODULATORS | COCENSYS, INC. (US) | 1993-08-11 | — | — | EP | claimed |
| US-5232917-A | Tranquillizers; antianxiolytic agents; sedatives; antidepressants; anticonvulsants; neurotransmitters | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-08-03 | — | — | US | claimed |
| WO-1993003732-A1 | GABA RECEPTOR MODULATORS | COCENSYS, INC. (US) | 1993-03-04 | — | — | WO | claimed |
| US-4061591-A | Selective adsorbent for use in affinity chromatography | PIERCE CHEMICAL COMPANY (US) | 1977-12-06 | — | — | US | claimed |
| US-12018320-B2 | Selective oxidation of 5-methylcytosine by TET-family proteins | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-06-25 | — | — | US | disclosed |
| EP-0850949-A2 | Novel derivatives for use in nucleic acid sequencing | INSTITUT PASTEUR (FR) | 1998-07-01 | — | — | EP | disclosed |
| EP-0850949-A2 | Novel derivatives for use in nucleic acid sequencing | INSTITUT PASTEUR (FR) | 1998-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197332-A1 | Modified Short Interfering RNA | NSUN2, NSUN3, METTL16 | ATAD2 1520/4885DYRK1A 2284/4885ADORA2A 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.